Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, and Australia. It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.…
Could Gelteq’s (GELS) Gel Improve Oral Drug Delivery?
Gelteq (NASDAQ: GELS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 0.2701 USD on 20 November 2026, down 70.4% over 52 weeks. Its 52-week range is 0.2599 USD to 2.010 USD: the price is 86.6% below the high and 3.9% above the low.
Its market capitalisation is 3.11M USD.
Gelteq reports return on equity of -42.0% and revenue down 62.4% year over year.
Its debt exceeds its cash by 6.24M AUD, a debt-to-equity ratio of 0.27. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.